Treatment with docetaxel (50mg/m2), CDDP (60mg/m2), S-1 (80mg/m2) and trastuzumab (6mg/kg) combination chemotherapy

3 trials

Sponsors

Tokushima-Hokkaido cancer therapy clinical trial group, Sapporo Medical University School of Medicine Dept. of Internal Medicine(4)

Conditions

gastric cancer

Unknown Phase

Feasibility study of S-1, docetaxel, cisplatin and trastuzumab combination chemotherapy (DCS-T) in patients with HER2-positive unresectable metastatic gastric cancer

Active, not recruitingJPRN-UMIN000005603

Tokushima-Hokkaido cancer therapy clinical trial groupgastric cancer

Start: 2011-06-01Target: 16Updated: 2026-06-29

Feasibility study of combination Docetaxel, Cisplatin, and S-1 as neoadjuvant chemotherapy for advanced gastric cancer.

RecruitingJPRN-UMIN000005984

Sapporo Medical University School of Medicine Dept. of Internal Medicine(4)gastric cancer

Start: 2011-06-01Target: 20Updated: 2026-06-29

Phase 2 study of S-1, docetaxel, cisplatin and trastuzumab combination chemotherapy (DCS-T) in patients with HER2-positive unresectable metastatic gastric cancer

RecruitingJPRN-UMIN000012042

Tokushima-Hokkaido cancer therapy clinical trial groupgastric cancer

Start: 2013-10-16Target: 30Updated: 2026-06-29

Related Papers

Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy.

2015-06-2323 citations

Trastuzumab (T-mab) in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: Feasibility and preliminary efficacy.

Journal of Clinical Oncology2014-01-20